No Data
No Data
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
復銳醫療科技:2023年度報告
Fu Rui Medical Technology (01696) Innovative Hyaluronic Acid Product Profhilo Launched in Hainan
Profhilo is an innovative hyaluronic acid that corrects/fills natural and induced skin depressions to help ease the physiological process of skin aging, including reducing skin hydration, adjusting dermal elastic fibers and collagen, and improving skin filling defects and dull skin tone.
Sisram Medical's Profit Down in Fiscal 2023
Sisram Medical (HKG:1696) recorded a decline in attributable profit for the year ended Dec. 31, 2023, to $31.5 million from $40.2 million during the year-ago period, a Wednesday filing on the Hong Kon
Press Release: Sisram Medical Announces 2023 Annual Results
Sisram Medical Announces 2023 Annual Results PR Newswire HONG KONG, March 20, 2024 Revenues of US$359.3M, with the direct sales portion reaching a record high HONG KONG, March 20, 2024 /PRNewswire
FuRui Medical Technology (01696) will pay a final dividend of HK$0.158 per share
FuRui Medical Technology (01696) announced that it will distribute final shares for the year ended December 31, 2023...
No Data